The Quantellect read.As of Nov 19, 2026, 5 active firms cover Adicet Bio Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $18.00 to $90.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $37.80 sits 1415% above the current $2.50. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-1.49 next quarter toward $-4.82 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$37.80
+1415.0% upside
Average target across 5 active firms as of Nov 19, 2026 vs $2.50 current
Highest Target$90.00
Average Target$37.80
Lowest Target$18.00
Detailed analyst forecasts for ACET
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate ACET a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ACET EPS & revenue forecast
EPS · NEXT QUARTER
$-1.49
Range $-2.10 – $-0.88 · 3 analysts · -21% YoY
Next period, 3 analysts expect Adicet Bio Inc to earn $-1.49 a share (range $-2.10 – $-0.88), versus $-1.88 a year earlier. Full-year consensus is $-7.33, growing to $-4.82 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Adicet Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACET.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$55.00+2104.4% to target
Overall win rate
50%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$34.00+1262.7% to target
Overall win rate
42%
+ Follow
#3
EW
Edward White
HC Wainwright & Co. · Rank #376
Neutral
No targeton ACET
Overall win rate
31%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #489
Neutral
No targeton ACET
Overall win rate
29%
+ Follow
#5
Robert Driscoll
Wedbush · Rank #490
Buy
$28.00+1022.2% to target
Overall win rate
32%
+ Follow
ACET stock forecast FAQ
What is ACET's average 12-month price target?+
The 5 active firms with a live target average $37.80 for Adicet Bio Inc over the next 12 months, ranging from a $90.00 high to a $18.00 low, as of Nov 19, 2026.
Is ACET stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ACET?+
The Street-high target is $90.00 (Guggenheim), and the Street-low is $18.00 (Canaccord Genuity). The average of all 5 active-firm targets is $37.80.
How many active Wall Street firms cover ACET?+
5 active firms have a recognized rating on Adicet Bio Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ACET?+
Among analysts who currently cover ACET, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $55.00 target.
What is Adicet Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-1.49 per share (range $-2.10 – $-0.88) across 3 analysts. Full-year EPS is projected at $-7.33, rising to $-4.82 the following year.
How much revenue is Adicet Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ACET lately?+
As of Nov 19, 2026, 5 of 5 active firms rate ACET a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACET calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.